Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease
Status:
Recruiting
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
KetaPal is a placebo-controlled randomized trial designed to demonstrate the antidepressant
action of ketamine in palliative care situations. Half of participants will receive Ketamine
and Milnacipran in combination, while the other half will receive a Placebo and Milnacipran
in combination.